Back to Search
Start Over
Comparative Effectiveness of COVID-19 Vaccines in Preventing Infections and Disease Progression from SARS-CoV-2 Omicron BA.5 and BA.2, Portugal.
- Source :
-
Emerging Infectious Diseases . Mar2023, Vol. 29 Issue 3, p569-575. 7p. 3 Charts. - Publication Year :
- 2023
-
Abstract
- We estimated comparative primary and booster vaccine effectiveness (VE) of SARS-CoV-2 Omicron BA.5 and BA.2 lineages against infection and disease progression. During April–June 2022, we implemented a case–case and cohort study and classified lineages using wholegenome sequencing or spike gene target failure. For the case–case study, we estimated the adjusted odds ratios (aORs) of vaccination using a logistic regression. For the cohort study, we estimated VE against disease progression using a penalized logistic regression. We observed no reduced VE for primary (aOR 1.07 [95% CI 0.93–1.23]) or booster (aOR 0.96 [95% CI 0.84–1.09]) vaccination against BA.5 infection. Among BA.5 case-patients, booster VE against progression to hospitalization was lower than that among BA.2 case-patients (VE 77% [95% CI 49%–90%] vs. VE 93% [95% CI 86%–97%]). Although booster vaccination is less effective against BA.5 than against BA.2, it offers substantial protection against progression from BA.5 infection to severe disease. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 10806040
- Volume :
- 29
- Issue :
- 3
- Database :
- Academic Search Index
- Journal :
- Emerging Infectious Diseases
- Publication Type :
- Academic Journal
- Accession number :
- 162150159
- Full Text :
- https://doi.org/10.3201/eid2903.221367